Ovarian Cancer

Experimental immunotherapy in clinical trials

Published in Women's Health Weekly, September 11th, 2003

Doctors at the University of Virginia Health System are primary investigators for a U.S. national, clinical research study involving an experimental immunotherapy treatment that shows promise in delaying or preventing the relapse of ovarian cancer in women who achieve remission after surgery and chemotherapy.

Two identical studies, called IMPACT I and II, are being conducted simultaneously by gynecologic cancer specialists at U.Va. and the University of California, Los Angeles (UCLA). The pivotal, confirmatory Phase III trial involves a new antibody called OvaRex (Unither Pharmaceuticals) that is thought to work by stimulating the body's immune system to recognize...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry